 |
Articles: General Pharma |
|
Receive free subspecialty "5-minute updates" via email
|
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Genentech, 12/08/09
Free full text
Visanne cleared for market launch in Europe as new treatment option for endometriosis
BayNews International, 12/08/09
Free full text
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Takeda Pharmaceuticals North America, 12/08/09 Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/08/09 Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Free full text
Cerner Enters R&D Pact with University
HealthDataManagement, 12/08/09 Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Free full text
New program helps educate survivors of a heart event about the importance of maintaining good physical and emotional health
Daiichi Sankyo, 12/08/09
Free full text
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09 Autologous blood therapy for common cold—A randomized, double-blind, placebo-controlled trial
Complementary Therapies in Medicine, 12/08/09 Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial
Nephrology Dialysis Transplantation, 12/08/09 Allos Therapeutics' FOLOTYN Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant
Allos Therapeutics, 12/08/09
Free full text
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals, 12/08/09
Free full text
Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma
Bristol Myers-Squibb Company, 12/08/09
Free full text
Forest Laboratories, Inc. to Host Analyst Meeting to Review the Company's Late-Stage Product Development Pipeline
Forest Laboratories, 12/08/09
Free full text
Cytokinetics Presents Non-Clinical Data Relating To CK-2017357 At The 5th Cachexia Conference
Cytokinetics, 12/08/09
Free full text
SAR3419 Phase I Study Results in non-Hodgkins Lymphoma at ASH
ImmunoGen, Inc., 12/08/09
Free full text
Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Amgen, 12/08/09
Free full text
Amgen Presents Data From First Nplate Study in Children With Chronic ITP
Amgen, 12/08/09
Free full text
Report: Acquisition Activity Down
HealthDataManagement, 12/08/09
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: U.S.Pharmacist, FDA Drug Alerts, Pharmiweb
more...
|
250 Available Pages
|
|
